Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/41858
Title: Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>
Authors: Tadeusz Robak
Huiqiang Huang
Jie Jin
Jun Zhu
Ting Liu
Olga Samoilova
Halyna Pylypenko
Gregor Verhoef
Noppadol Siritanaratkul
Evgenii Osmanov
Juliana Pereira
Jiri Mayer
Xiaonan Hong
Rumiko Okamoto
Lixia Pei
Brendan Rooney
Helgi van de Velde
Franco Cavalli
Medical University of Lodz
Sun Yat-Sen University Cancer Center
Zhejiang University School of Medicine
Beijing Cancer Hospital
West China Hospital of Sichuan University
Lobachevsky State University of Nizhni Novgorod
null
KU Leuven– University Hospital Leuven
Mahidol University
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Universidade de Sao Paulo - USP
Fakultni Nemocnice Brno
Fudan University Shanghai Cancer Center
Tokyo Metropolitan Komagome Hospital
Janssen
Janssen Research and Development
Takeda Oncology
Ospedale San Giovanni
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 5-Jun-2017
Citation: Leukemia and Lymphoma. (2017), 1-8
Abstract: © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed ≥6 cycles of treatment. From the end of cycle 6, patients receiving ≥4.6 mg/m2/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m2/cycle by univariate analysis (HR 0.43 [95% CI: 0.23–0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20–0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020251694&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/41858
ISSN: 10292403
10428194
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.